Literature DB >> 8620480

Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis.

J Hasegawa1, S Kamada, W Kamiike, S Shimizu, T Imazu, H Matsuda, Y Tsujimoto.   

Abstract

Fas (Apo-1/CD95) belongs to the tumor necrosis factor/nerve growth factor receptor family and transmits apoptotic signals by binding to its ligand. Interleukin-1beta-converting enzyme (ICE), which shows substantial homology to the product of the cell death gene, ced-3, of Caenorhabditis elegans, is reported to be involved in Fas-mediated apoptosis. Using two human carcinoma-derived cell lines with undetectable levels of ICE, we found that an agonistic antihuman Fas antibody induces the activation of CPP32/Yama(-like) proteases that are ICE(-like) protease family members, and that a tetrapeptide inhibitor of CPP32/Yama protease, DEVD-CHO, inhibits the Fas-mediated activation of the proteases, Fas-mediated apoptosis, and CPP32/Yama(-like) proteolytic activities in vitro. Fas-mediated apoptosis is inhibited by the CPP32/Yama inhibitor DEVD-CHO, but not by the ICE inhibitor YVAD-CHO, suggesting a dominant role for the CPP32/Yama(-like) proteases and not ICE itself in Fas-mediated apoptosis of the human carcinoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620480

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fas-mediated cell death.

Authors:  A Suzuki; Y Tsutomi; N Yamamoto; T Shibutani; K Akahane
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

Review 2.  Molecular steps of cell suicide: an insight into immune senescence.

Authors:  S Gupta
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

3.  A functional role for death proteases in s-Myc- and c-Myc-mediated apoptosis.

Authors:  S Kagaya; C Kitanaka; K Noguchi; T Mochizuki; A Sugiyama; A Asai; N Yasuhara; Y Eguchi; Y Tsujimoto; Y Kuchino
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

4.  Transforming growth factor beta1 attenuates ceramide-induced CPP32/Yama activation and apoptosis in human leukaemic HL-60 cells.

Authors:  M L Kuo; C W Chen; S H Jee; S E Chuang; A L Cheng
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

5.  Light-activated nanoimpeller-controlled drug release in cancer cells.

Authors:  Jie Lu; Eunshil Choi; Fuyuhiko Tamanoi; Jeffrey I Zink
Journal:  Small       Date:  2008-04       Impact factor: 13.281

6.  Respiratory syncytial virus infection of human alveolar epithelial cells enhances interferon regulatory factor 1 and interleukin-1beta-converting enzyme gene expression but does not cause apoptosis.

Authors:  R Takeuchi; H Tsutsumi; M Osaki; K Haseyama; N Mizue; S Chiba
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

7.  FLICE is activated by association with the CD95 death-inducing signaling complex (DISC).

Authors:  J P Medema; C Scaffidi; F C Kischkel; A Shevchenko; M Mann; P H Krammer; M E Peter
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

8.  Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines.

Authors:  P Utaisincharoen; S Ubol; N Tangthawornchaikul; P Chaisuriya; S Sirisinha
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

9.  Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation.

Authors:  Francis M Hughes; Nivardo P Vivar; James G Kennis; Jeffery D Pratt-Thomas; Danielle W Lowe; Brooke E Shaner; Paul J Nietert; Laura S Spruill; J Todd Purves
Journal:  Am J Physiol Renal Physiol       Date:  2013-11-27

Review 10.  [Value of targeted treatment for testicular cancer: from molecular approaches to clinical possibilities].

Authors:  A Martinschek; C G Ruf; C Sparwasser; H U Schmelz
Journal:  Urologe A       Date:  2008-10       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.